Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.
COX-2
EGFR
PI3K-AKT
gefitinib resistance
non-small cell lung cancer
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
12
2019
accepted:
02
03
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
15
4
2020
Statut:
epublish
Résumé
Gefitinib is a potent inhibitor of EGFR and represents the front-line treatment for non-small cell lung cancer (NSCLC) therapeutics. However, NSCLC patients are prone to develop acquired resistance through as yet, undefined mechanisms of resistance. Here, we investigated the role of COX-2 during gefitinib resistance in NSCLC cells and revealed its underlying mechanism(s) of action. We report the upregulation of COX-2 in gefitinib-resistant NSCLC tissues and cells, which is associated with poor prognosis.
Identifiants
pubmed: 32284763
doi: 10.7150/jca.42850
pii: jcav11p3667
pmc: PMC7150449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3667-3674Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Pharmacogenomics. 2015 Nov;16(16):1843-62
pubmed: 26555006
Cancer Lett. 2007 Jun 28;251(2):237-46
pubmed: 17189670
J Cell Mol Med. 2018 May;22(5):2856-2864
pubmed: 29516630
Eur J Cancer. 1996 Nov;32A(12):2070-4
pubmed: 9014747
J Clin Oncol. 2005 Jan 10;23(2):254-66
pubmed: 15637389
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6161-9
pubmed: 17062693
Apoptosis. 2013 Nov;18(11):1437-1446
pubmed: 23851982
Cancer Cell. 2010 Apr 13;17(4):319-32
pubmed: 20385358
Oncotarget. 2017 Nov 30;8(67):111246-111257
pubmed: 29340050
Cancer Res. 2009 Apr 15;69(8):3256-61
pubmed: 19351834
Mol Cancer Res. 2006 Aug;4(8):539-47
pubmed: 16908593
Front Oncol. 2019 Nov 05;9:1167
pubmed: 31750252
Oncotarget. 2014 Sep 15;5(17):7328-41
pubmed: 25193862
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancer Cell. 2009 Jun 2;15(6):489-500
pubmed: 19477428
Cancer Cell. 2014 Sep 8;26(3):358-373
pubmed: 25203322
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
pubmed: 18227510
J Cell Mol Med. 2018 Mar;22(3):1923-1930
pubmed: 29363879
Oncogene. 2007 May 31;26(26):3789-96
pubmed: 17213821
Oncol Res. 2020 Mar 27;28(2):147-159
pubmed: 31711559
Cancer Cell. 2012 Dec 11;22(6):699-701
pubmed: 23238008
Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36
pubmed: 11894011
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
Biochem Pharmacol. 2012 Jun 15;83(12):1613-22
pubmed: 22414725
Int J Oncol. 2014 Oct;45(4):1583-93
pubmed: 25017791
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Sci Rep. 2019 Nov 15;9(1):16913
pubmed: 31729456
Nat Med. 2012 Mar 18;18(4):521-8
pubmed: 22426421
Annu Rev Biochem. 2000;69:145-82
pubmed: 10966456
Cancer Res. 2007 Jun 15;67(12):5587-93
pubmed: 17575121
Pharmacol Ther. 2017 Jun;174:1-21
pubmed: 28167215
Cancer Res. 2006 Dec 15;66(24):11700-8
pubmed: 17178865
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Hepatology. 2012 Jun;55(6):1787-98
pubmed: 22271581
Toxicology. 2011 Jan 11;279(1-3):36-44
pubmed: 20849910
Recent Results Cancer Res. 2018;211:235-246
pubmed: 30069771
Am J Clin Oncol. 2005 Dec;28(6):560-4
pubmed: 16317264
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Future Oncol. 2005 Aug;1(4):449-60
pubmed: 16556021
BMC Cancer. 2018 Aug 2;18(1):780
pubmed: 30068310
Int J Cancer. 1997 Mar 17;70(6):722-6
pubmed: 9096655
Cancer Cell Int. 2013 Feb 13;13(1):15
pubmed: 23402326
J Thorac Oncol. 2012 Nov;7(11):1640-4
pubmed: 22899358
Mol Cancer Res. 2009 Aug;7(8):1367-77
pubmed: 19671676
J Natl Cancer Inst. 2006 Jun 7;98(11):736-47
pubmed: 16757698